|
VTA1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62525548574877E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.18716148023168E-12 |
| Normal-vs-Stage2 |
1.62129998315663E-09 |
| Normal-vs-Stage3 |
1.19104726081787E-12 |
| Normal-vs-Stage4 |
1.62891922173003E-12 |
| Stage1-vs-Stage2 |
4.864000E-01 |
| Stage1-vs-Stage3 |
1.209810E-01 |
| Stage1-vs-Stage4 |
1.598510E-03 |
| Stage2-vs-Stage3 |
6.765400E-01 |
| Stage2-vs-Stage4 |
8.418400E-02 |
| Stage3-vs-Stage4 |
1.232830E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.88578058618805E-15 |
| Normal-vs-AfricanAmerican |
1.60578999999217E-05 |
| Normal-vs-Asian |
1.65799995954785E-09 |
| Caucasian-vs-AfricanAmerican |
4.697800E-01 |
| Caucasian-vs-Asian |
6.678600E-01 |
| AfricanAmerican-vs-Asian |
7.000600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.77635683940025E-15 |
| Normal-vs-Female |
1.71584968455818E-12 |
| Male-vs-Female |
4.787500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.08980047208718E-10 |
| Normal-vs-Age(41-60Yrs) |
2.1094237467878E-15 |
| Normal-vs-Age(61-80Yrs) |
2.66431321449545E-12 |
| Normal-vs-Age(81-100Yrs) |
2.404300E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.801700E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.012190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.424800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.291600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.468600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.794200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.207400E-01 |
| Classical-VS-Follicular |
8.584400E-02 |
| Classical-VS-Other |
1.937570E-01 |
| Classical-VS-Normal |
2.07101003013577E-12 |
| Tall-VS-Follicular |
9.141000E-01 |
| Tall-VS-Other |
5.075000E-01 |
| Tall-VS-Normal |
1.47990000032294E-07 |
| Follicular-VS-Other |
5.293000E-01 |
| Follicular-VS-Normal |
3.02700087218E-11 |
| Other-VS-Normal |
1.383490E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.73034936274053E-14 |
| Normal-vs-N1 |
6.56030785251005E-13 |
| N0-vs-N1 |
9.915500E-02 |
|
|
